Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial.
Saved in:
| Title: | Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial. |
|---|---|
| Authors: | Vermeire, Séverine1 (AUTHOR) Severine.Vermeire@uzleuven.be, D'Haens, Geert2 (AUTHOR), Baert, Filip3 (AUTHOR), Danese, Silvio4 (AUTHOR), Kobayashi, Taku5 (AUTHOR), Loftus, Edward V6 (AUTHOR), Bhatia, Siddharth7 (AUTHOR), Agboton, Christian8 (AUTHOR), Rosario, Maria7 (AUTHOR), Chen, Chunlin7 (AUTHOR), Zhang, Wenwen7 (AUTHOR), Kisfalvi, Krisztina7 (AUTHOR), Sandborn, William J9 (AUTHOR) |
| Source: | Journal of Crohn's & Colitis. Jan2022, Vol. 16 Issue 1, p27-38. 12p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
